Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões

By João L. Carapinha

February 12, 2026

Robotic Surgery Portugal Achieves Historic First at ULS Viseu Dão-Lafões Robotic surgery Portugal has reached a new milestone with the successful first procedure at the Local Health Unit (ULS) Viseu Dão-Lafões...
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa

By João L. Carapinha

Pharmaceutical Tender Investigation Targets Ascendis, Pharma Q, and Sonke The Competition Commission of South Africa has launched a pharmaceutical tender investigation into manufacturers Ascendis, Pharma Q, and...
Strategic Vision and Infarmed 2026 Priorities for Regulatory Reform

By João L. Carapinha

Infarmed 2026 Priorities Take Shape in Leadership Summit Infarmed 2026 priorities crystallized during the Executive Board's February 11, 2026, session with unit directors, led by President Rui Santos Ivo, Vice-President Raque...
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion in FY 2025

By João L. Carapinha

February 11, 2026

AstraZeneca's financial results for FY and Q4 2025 showcased total revenue of $58.7 billion, up 8% at constant exchange rates (CER) from FY 2024, driven by oncology leadershi...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Resistant Cases

By João L. Carapinha

KEYTRUDA Ovarian Cancer Treatments Gain FDA Nod KEYTRUDA ovarian cancer treatments now include FDA-approved regimens of KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), each with paclitaxel ±...
South Africa Health Reform: Navigating Innovations and Challenges for 2026

By João L. Carapinha

February 10, 2026

South Africa Health Reform: Contrasts in 2026 Public Health Agenda South Africa health reform defines the 2026 public health landscape as a mix of breakthroughs like HIV prevention injections and AI-driven TB diagnos...
View All News
Search By Category

Syenza's Top Picks

CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals

2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solutions

WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults

Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft Annual Work Programme 2026

Preparing for the EU Health Technology Assessment: Key Insights from the Upcoming 2026 Webinar

EU Launches Joint Scientific Consultations to Enhance Health Technology Assessment

Medicare Drug Price Negotiations: Major Savings for Seniors on Cancer and Chronic Disease Medications by 2027

Latest

Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões

By João L. Carapinha

February 12, 2026

Robotic Surgery Portugal Achieves Historic First at ULS Viseu Dão-Lafões Robotic surgery Portugal has reached a new milestone with the successful first procedure at the Local Health Unit (ULS) Viseu Dão-Lafões...

Latest

Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa

By João L. Carapinha

Pharmaceutical Tender Investigation Targets Ascendis, Pharma Q, and Sonke The Competition Commission of South Africa has launched a pharmaceutical tender investigation into manufacturers Ascendis, Pharma Q, and...

Latest

Strategic Vision and Infarmed 2026 Priorities for Regulatory Reform

By João L. Carapinha

Infarmed 2026 Priorities Take Shape in Leadership Summit Infarmed 2026 priorities crystallized during the Executive Board's February 11, 2026, session with unit directors, led by President Rui Santos Ivo, Vice-President Raque...

Latest

AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion in FY 2025

By João L. Carapinha

February 11, 2026

AstraZeneca's financial results for FY and Q4 2025 showcased total revenue of $58.7 billion, up 8% at constant exchange rates (CER) from FY 2024, driven by oncology leadershi...

Global Updates

Advancements in Uncertainty-Aware Diagnostics with ConfiDx LLM

By João L. Carapinha

February 10, 2026

ConfiDx Ushers in Uncertainty-Aware Diagnostics Uncertainty-aware diagnostics are transforming clinical decision-making through ConfiDx, a large language model (LLM) trained to recognize diagnostic uncertainty in cases with limited cl...

Global Updates

National HealthTech Access: Transforming NHS Adoption and Equity

By João L. Carapinha

February 9, 2026

HealthTech NHS Access Revolutionized by National Programme HealthTech NHS Access is set to transform through the National HealthTech Access Programme (NHAP), announced by

Global Updates

Launch of TrumpRx Drug Pricing: Savings on Essential Medications

By João L. Carapinha

February 6, 2026

TrumpRx Drug Pricing Launches with Massive Discounts President Donald J. Trump announced the launch of TrumpRx.gov on February 5, 2026, as a cornerstone of TrumpRx drug pricing reforms, enabling American patients to access signif...

Global Updates

Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthrough Treatment

By HEOR Staff Writer

February 4, 2026

Datroway metastatic breast cancer treatment has gained Priority Review from the US Food and Drug Administration (FDA) for first-line use in adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) ineligible for PD-1/PD-L1 inhibitors. This milestone for AstraZeneca and ...

Europe

View All
Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões

By João L. Carapinha

February 12, 2026

Robotic Surgery Portugal Achieves Historic First at ULS Viseu Dão-Lafões Robotic surgery Portugal has reached a new milestone with the successful first procedure at the Local Health Unit (ULS) Viseu Dão-Lafões...
Strategic Vision and Infarmed 2026 Priorities for Regulatory Reform

By João L. Carapinha

Infarmed 2026 Priorities Take Shape in Leadership Summit Infarmed 2026 priorities crystallized during the Executive Board's February 11, 2026, session with unit directors, led by President Rui Santos Ivo, Vice-President Raque...
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion in FY 2025

By João L. Carapinha

February 11, 2026

AstraZeneca's financial results for FY and Q4 2025 showcased total revenue of $58.7 billion, up 8% at constant exchange rates (CER) from FY 2024, driven by oncology leadershi...
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes

By HEOR Staff Writer

February 10, 2026

Unlocking Early-Stage Cancer Treatment Gains Early-stage cancer treatment offers significant clinical, humanistic, and economic advantages through timely detection and intervention, yet faces barriers like screening disparities, recurren...

North America

View All
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion in FY 2025

By João L. Carapinha

February 11, 2026

AstraZeneca's financial results for FY and Q4 2025 showcased total revenue of $58.7 billion, up 8% at constant exchange rates (CER) from FY 2024, driven by oncology leadershi...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Resistant Cases

By João L. Carapinha

KEYTRUDA Ovarian Cancer Treatments Gain FDA Nod KEYTRUDA ovarian cancer treatments now include FDA-approved regimens of KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), each with paclitaxel ±...
Advancements in Uncertainty-Aware Diagnostics with ConfiDx LLM

By João L. Carapinha

February 10, 2026

ConfiDx Ushers in Uncertainty-Aware Diagnostics Uncertainty-aware diagnostics are transforming clinical decision-making through ConfiDx, a large language model (LLM) trained to recognize diagnostic uncertainty in cases with limited cl...
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes

By HEOR Staff Writer

Unlocking Early-Stage Cancer Treatment Gains Early-stage cancer treatment offers significant clinical, humanistic, and economic advantages through timely detection and intervention, yet faces barriers like screening disparities, recurren...

Sub-Saharan Africa

View All
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa

By João L. Carapinha

February 12, 2026

Pharmaceutical Tender Investigation Targets Ascendis, Pharma Q, and Sonke The Competition Commission of South Africa has launched a pharmaceutical tender investigation into manufacturers Ascendis, Pharma Q, and...
South Africa Health Reform: Navigating Innovations and Challenges for 2026

By João L. Carapinha

February 10, 2026

South Africa Health Reform: Contrasts in 2026 Public Health Agenda South Africa health reform defines the 2026 public health landscape as a mix of breakthroughs like HIV prevention injections and AI-driven TB diagnos...
Enhancing Patient Safety in Africa’s Healthcare Transformation

By HEOR Staff Writer

February 2, 2026

Prioritizing Patient Safety Africa in 2026 Trends Patient safety Africa stands at the forefront as regulatory bodies drive healthcare self-reliance amid global shifts. A recent article (linked below) outlines five pivotal trends pro...
Navigating Economic Resilience Through Life Sciences Investment

By João L. Carapinha

January 20, 2026

Navigating a Leaderless Global Economy Through Life Sciences Investment In an era of deepening geopolitical fragmentation, often termed the G-Zero world, global governments are urged to prioritize bold life sci...